Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis.

Leonard Amaral, J. Molnár

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Advances recently introduced into the Clinical Mycobacteriology Laboratory of the Institute of Hygiene and Tropical Medicine, such that a multi-drug resistant infection of pulmonary tuberculosis (MDR TB) can be identified within one day of receiving the sputum specimen, have greatly contributed to the reduction of the frequency of these infections. However, approximately 50% of reduced infections exhibit a phenotype that is consistent with that presented by an extensively drug-resistant (XDR) infection. More effective agents were required and hence attention was attributed to the possibility that the old neuroleptic phenothiazine thioridazine (TZ), previously shown to inhibit the growth of all encountered strains of Mycobacterium tuberculosis (Mtb) regardless of their antibiotic resistance profile, could be eventually used for therapy of problematic MDR/XDR TB infections. This mini-review discusses the mechanisms that render TZ an effective adjuvant to antibiotics to which the initial infective agent Mtb was resistant.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalIn Vivo
Volume28
Issue number2
Publication statusPublished - 2014

Fingerprint

Thioridazine
Pulmonary Tuberculosis
Clinical laboratories
Anti-Bacterial Agents
Infection
Pharmaceutical Preparations
Antipsychotic Agents
Medicine
Mycobacterium tuberculosis
Extensively Drug-Resistant Tuberculosis
Tropical Medicine
Microbial Drug Resistance
Sputum
Hygiene
Phenotype
Growth
phenothiazine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis. / Amaral, Leonard; Molnár, J.

In: In Vivo, Vol. 28, No. 2, 2014, p. 267-271.

Research output: Contribution to journalArticle

@article{14d19b90712248f68b2a391259a5228e,
title = "Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis.",
abstract = "Advances recently introduced into the Clinical Mycobacteriology Laboratory of the Institute of Hygiene and Tropical Medicine, such that a multi-drug resistant infection of pulmonary tuberculosis (MDR TB) can be identified within one day of receiving the sputum specimen, have greatly contributed to the reduction of the frequency of these infections. However, approximately 50{\%} of reduced infections exhibit a phenotype that is consistent with that presented by an extensively drug-resistant (XDR) infection. More effective agents were required and hence attention was attributed to the possibility that the old neuroleptic phenothiazine thioridazine (TZ), previously shown to inhibit the growth of all encountered strains of Mycobacterium tuberculosis (Mtb) regardless of their antibiotic resistance profile, could be eventually used for therapy of problematic MDR/XDR TB infections. This mini-review discusses the mechanisms that render TZ an effective adjuvant to antibiotics to which the initial infective agent Mtb was resistant.",
author = "Leonard Amaral and J. Moln{\'a}r",
year = "2014",
language = "English",
volume = "28",
pages = "267--271",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis.

AU - Amaral, Leonard

AU - Molnár, J.

PY - 2014

Y1 - 2014

N2 - Advances recently introduced into the Clinical Mycobacteriology Laboratory of the Institute of Hygiene and Tropical Medicine, such that a multi-drug resistant infection of pulmonary tuberculosis (MDR TB) can be identified within one day of receiving the sputum specimen, have greatly contributed to the reduction of the frequency of these infections. However, approximately 50% of reduced infections exhibit a phenotype that is consistent with that presented by an extensively drug-resistant (XDR) infection. More effective agents were required and hence attention was attributed to the possibility that the old neuroleptic phenothiazine thioridazine (TZ), previously shown to inhibit the growth of all encountered strains of Mycobacterium tuberculosis (Mtb) regardless of their antibiotic resistance profile, could be eventually used for therapy of problematic MDR/XDR TB infections. This mini-review discusses the mechanisms that render TZ an effective adjuvant to antibiotics to which the initial infective agent Mtb was resistant.

AB - Advances recently introduced into the Clinical Mycobacteriology Laboratory of the Institute of Hygiene and Tropical Medicine, such that a multi-drug resistant infection of pulmonary tuberculosis (MDR TB) can be identified within one day of receiving the sputum specimen, have greatly contributed to the reduction of the frequency of these infections. However, approximately 50% of reduced infections exhibit a phenotype that is consistent with that presented by an extensively drug-resistant (XDR) infection. More effective agents were required and hence attention was attributed to the possibility that the old neuroleptic phenothiazine thioridazine (TZ), previously shown to inhibit the growth of all encountered strains of Mycobacterium tuberculosis (Mtb) regardless of their antibiotic resistance profile, could be eventually used for therapy of problematic MDR/XDR TB infections. This mini-review discusses the mechanisms that render TZ an effective adjuvant to antibiotics to which the initial infective agent Mtb was resistant.

UR - http://www.scopus.com/inward/record.url?scp=84908502585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908502585&partnerID=8YFLogxK

M3 - Article

C2 - 24632985

AN - SCOPUS:84908502585

VL - 28

SP - 267

EP - 271

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 2

ER -